ArticleScientific reports2025
Epidemiology, antifungal susceptibility and biological characteristics of clinical Aspergillus fumigatus in a tertiary hospital.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A long noncoding RNA regulates in vitro and in vivo triazole antifungal susceptibility in Aspergillus fumigatus.Genetics · 2026Article
- Molecular and Phenotypic Characterization of Multidrug-ResistantJournal of fungi (Basel, Switzerland) · 2026Article
- Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026Review
- Molecular mechanisms drivingFrontiers in molecular biosciences · 2026Review
- Antifungal susceptibility ofFrontiers in public health · 2026Article
- Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Agricultural SDHIs Induce Azole Resistance in Aspergillus fumigatus via Mitochondrial Sdh1 Suppression.Mycopathologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Azole resistance in Aspergillus fumigatus poses a significant clinical challenge globally. In this study, we analyzed 307 clinical A. fumigatus isolates from General Hospital of Ningxia Medical University in China, collected between July 2023 and July 2024, to explore their susceptibility profiles, genotypic characteristics and biological traits. The overall frequency of azole resistance among clinical isolates in Ningxia province was found to be 1.20% (7 azole-resistant A. fumigatus, designated AF1-AF7), each exhibiting distinct phenotypes in terms of azole resistance, spore viability, and resilience to environmental stress. Among these strains, the cyp51A mutations predominantly included TR43/L98H, while the hmg1 mutations were primarily S212P/Y564H. Additionally, novel mutations were discovered in cyp51B, specifically the t-215c point mutation and a base deletion (gatgccta) in the - 213 to - 206 region. The AF3 strain demonstrated the highest spore activity and anti-SDS efficacy. In contrast, the AF1 and AF2 strains were resistant to three azoles and also exhibited resistance to Menadione, similar to AF7. Notably, six out of the seven strains displayed resistance to NaCl and KCl, indicating a strong tolerance to saline conditions. These findings suggest that azole-resistant strains possess varying degrees of resistance to environmental stressors, implying that they may adapt to their surroundings through different evolutionary pathways, which could complicate clinical treatment strategies. Effective surveillance and control strategies are essential to control the widespread prevalence of azole-resistant A. fumigatus and to reduce the risk of infection in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.